STOCKHOLM, June 30th 2020. During June 2020, the registered number of shares and votes in Moberg Pharma AB (OMX: MOB) (“Moberg Pharma” or the “Company”) has increased due to conversion of convertible notes issued pursuant to the financing agreement entered into between the Company and Nice & Green S.A. on March 23rd, 2020.
Price-sensitive press releases
2020-06-25
STOCKHOLM, June 25th, 2020, Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox. Mycological cure was achieved in 84 percent of patients, which is unprecedented for a topical treatment and even higher than reported for oral treatments. The pattern is consistent with the results from the North American Phase 3 study, with low complete cure rates despite the high mycological cure rates. Moberg Pharma will discuss next steps with partners and regulatory agencies.
2020-05-29
STOCKHOLM, May 29th, 2020, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 19,223,510. The 370,000 newly issued shares are held by the company to secure its commitments under incentive programmes.
2020-05-29
STOCKHOLM, May 29th, 2020, Moberg Pharma AB (OMX: MOB) announced that the total number of common shares in the company has increased to 19,223,510. The 370,000 newly issued shares are held by the company to secure its commitments under incentive programmes.
2020-05-19
STOCKHOLM, May 19th, 2020, Moberg Pharma AB (OMX: MOB) announced that the board of directors exercises authorizations to issue and repurchase C-shares, and converts C-shares to common shares, to secure the company’s commitments under incentive programme.
2020-05-12
FINANCING AGREEMENT OF UP TO SEK 216 MILLION FOR FURTHER INVESTMENTS IN MOB-015
2020-05-05
STOCKHOLM, May 5th, 2020 - On May 12th, 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July 2019 - March 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2020-04-28
STOCKHOLM, April 28th, 2020. Moberg Pharma AB (publ)’s (“Moberg Pharma” or the “Company”) Extraordinary General Meeting took place today in the Company’s premises in Bromma. The Extraordinary General Meeting resolved as set out below.
2020-03-27
The shareholders in Moberg Pharma AB (publ) (reg. no. 556697-7426) (the “Company” or “Moberg Pharma”) are hereby convened to the Extraordinary General Meeting on Tuesday, 28 April 2020 at 4:30 p.m. (CET) in the Company’s premises in Bromma, address Gustavslundsvägen 42, 5 tr, 167 51 Bromma (Alviks torg), Sweden.
2020-03-23
Moberg Pharma enters financing agreement of up to SEK 216 million for further investments in MOB-015
STOCKHOLM, March 23[rd], 2020 - Moberg Pharma AB (publ) announces today that the company has entered into a convertible note agreement with Nice & Green S.A. (“N&G”), contingent on an authorization at an Extraordinary General Meeting. In December 2019, the company reported that the primary endpoint for MOB-015 was met in the North American phase 3 study. The evaluation of the study results showed that the rapid and high antifungal effect of MOB-015 is world leading, but that dosing may be optimized. Based on these data, MOB-015 has the potential to become the future market leader in onychomycosis. The agreement with N&G enables Moberg Pharma to pursue this potential and conduct an additional clinical study, depending on the outcome of the EU study expected at the end of Q2 2020.
2020-02-11
PRIMARY ENDPOINT REACHED IN THE PHASE 3 STUDY
2020-02-04
STOCKHOLM, February 4[th], 2020 - On February 11[th], 2020, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for July - December 2020. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.
2020-01-22
STOCKHOLM, January 22[nd], 2020. Moberg Pharma AB (OMX: MOB) has now completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and increased the understanding of the study outcomes. Key conclusions include: i) MOB-015 delivers a very high mycological cure rate that compares favorably to oral antifungal drugs with the added advantage of an earlier onset of action; ii) Confirmation that the proprietary vehicle technology increases the hydration and permeability of the nail plate enabling efficient terbinafine delivery, however it also confounds the assessment of clinical cure and complete cure and iii) A likely solution to the problem – a shorter dosing regimen with the potential to deliver superior complete cure rates.
2020-01-14
Moberg Pharma AB (OMX: MOB) announces that the Swedish Tax Agency has published a notification on distribution of the acquisition cost of shares as a consequence of the redemption in 2019 of shares in Moberg Pharma AB for cash proceeds of SEK 46.50 per share.